Objective:
To evaluate the association between GLP-1 receptor agonists, particularly semaglutide, and the risk of ischaemic optic neuropathy (ION) using FDA adverse event reports.
Key Findings:
- Semaglutide was the only GLP-1RA associated with a significant signal for ION.
- Wegovy showed the strongest association with ION, nearly five times higher risk compared to Ozempic.
- No ION cases were reported with oral semaglutide (Rybelsus).
- Men receiving Wegovy had particularly high reporting odds for ION, while Ozempic cases were more common in women.
- No signal for ION was detected with tirzepatide or comparator drugs like metformin and insulin.
Interpretation:
The findings suggest a potential safety signal for ION associated with high-dose semaglutide, particularly Wegovy, warranting further investigation.
Limitations:
- No direct clinical link established between semaglutide and ION.
- Observational nature of the analysis limits causal inference.
Conclusion:
Further prospective studies are needed to clarify the relationship between semaglutide and NAION risk, especially regarding specific formulations and patient demographics.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
